



# ***Streptococcus pluranimalium* 2N12 Exerts an Antagonistic Effect Against the Swine Pathogen *Actinobacillus pleuropneumoniae* by Producing Hydrogen Peroxide**

**Katy Vaillancourt<sup>1</sup>, Michel Frenette<sup>1,2</sup>, Marcelo Gottschalk<sup>2,3</sup> and Daniel Grenier<sup>1,2\*</sup>**

<sup>1</sup> Groupe de Recherche en Écologie Buccale, Faculté de Médecine Dentaire, Université Laval, Québec City, QC, Canada,

<sup>2</sup> Centre de Recherche en Infectiologie Porcine et Avicole, Fonds de Recherche du Québec-Nature et Technologies, Saint-Hyacinthe, QC, Canada, <sup>3</sup> Groupe de Recherche sur les Maladies Infectieuses du Porc, Faculté de Médecine Vétérinaire, Université de Montréal, Saint-Hyacinthe, QC, Canada

## OPEN ACCESS

### Edited by:

Fabrizio Bertelloni,  
University of Pisa, Italy

### Reviewed by:

Patrick Blackall,  
The University of  
Queensland, Australia  
Ciro Cesar Rossi,  
Federal University of Rio de  
Janeiro, Brazil  
Andrew N. Rycroft,  
Royal Veterinary College (RVC),  
United Kingdom

### \*Correspondence:

Daniel Grenier  
daniel.grenier@greb.ulaval.ca

### Specialty section:

This article was submitted to  
Veterinary Infectious Diseases,  
a section of the journal  
Frontiers in Veterinary Science

**Received:** 30 September 2021

**Accepted:** 16 November 2021

**Published:** 08 December 2021

### Citation:

Vaillancourt K, Frenette M,  
Gottschalk M and Grenier D (2021)  
*Streptococcus pluranimalium* 2N12  
Exerts an Antagonistic Effect Against  
the Swine Pathogen *Actinobacillus*  
*pleuropneumoniae* by Producing  
Hydrogen Peroxide.  
Front. Vet. Sci. 8:787241.  
doi: 10.3389/fvets.2021.787241

*Actinobacillus pleuropneumoniae* is the causal agent of porcine pleuropneumonia, a highly contagious and often deadly respiratory disease that causes major economic losses in the swine industry worldwide. The aim of the present study was to investigate the hydrogen peroxide (H<sub>2</sub>O<sub>2</sub>)-dependent antagonistic activity of *Streptococcus pluranimalium* 2N12 (pig nasal isolate) against *A. pleuropneumoniae*. A fluorimetric assay showed that *S. pluranimalium* produces H<sub>2</sub>O<sub>2</sub> dose- and time-dependently. The production of H<sub>2</sub>O<sub>2</sub> increased in the presence of exogenous lactate, suggesting the involvement of lactate oxidase. All 20 strains of *A. pleuropneumoniae* tested, belonging to 18 different serovars, were susceptible to H<sub>2</sub>O<sub>2</sub>, with minimal inhibitory concentrations and minimal bactericidal concentrations ranging from 0.57 to 2.3 mM. H<sub>2</sub>O<sub>2</sub>, as well as a culture supernatant of *S. pluranimalium*, killed planktonic cells of *A. pleuropneumoniae*. Treating the culture supernatant with catalase abolished its bactericidal property. H<sub>2</sub>O<sub>2</sub> was also active against a pre-formed biofilm-like structure of *A. pleuropneumoniae* albeit to a lesser extent. A checkerboard assay was used to show that there were antibacterial synergistic interactions between H<sub>2</sub>O<sub>2</sub> and conventional antibiotics, more particularly ceftiofur. Based on our results and within the limitations of this *in vitro* study, the production of H<sub>2</sub>O<sub>2</sub> by *S. pluranimalium* could be regarded as a potential protective mechanism of the upper respiratory tract against H<sub>2</sub>O<sub>2</sub>-sensitive pathogens such as *A. pleuropneumoniae*.

**Keywords:** *Actinobacillus pleuropneumoniae*, *Streptococcus pluranimalium*, porcine pleuropneumonia, swine infection, hydrogen peroxide, antagonism

## INTRODUCTION

*Actinobacillus pleuropneumoniae* is a Gram-negative facultative anaerobic encapsulated coccobacillus. It is classified into two biotypes: biotype 1 requires nicotinamide adenine dinucleotide (NAD) to grow while biotype 2 is NAD independent (1). Based on their antigenic composition and the properties of their lipopolysaccharides (LPS) and capsular polysaccharides,

nineteen serovars of *A. pleuropneumoniae* have been described to date (2, 3). This bacterium is transmitted from pig to pig mainly by direct oral and nasal contact or by bioaerosols following the introduction of asymptomatic carrier pigs into a herd or piggery (2). *A. pleuropneumoniae* is a respiratory pathogen that colonizes the tonsils and nasal cavities of pigs and causes porcine pleuropneumonia, a highly contagious and often deadly respiratory disease responsible for significant economic losses in the swine industry worldwide (1). This disease, for which the clinical features range from peracute to chronic, is characterized by the presence of hemorrhagic, fibrinous, and necrotic lung lesions. The serovars most often isolated from infections differ depending on the region of the world. In North America, serovars 5 and 7 are predominant while serovars 2 and 9/11 are most often isolated in European countries (2, 4–7). The use of antibiotics at the onset of the disease is the most effective treatment for diminishing the severity of the clinical symptoms, the death rate, and the spread of infections (1, 2).

*A. pleuropneumoniae* produces a broad array of virulence factors that play crucial roles in the infectious process of porcine pleuropneumonia by contributing to colonization, evasion of the immune defense mechanisms, and induction of lung lesions (2, 8, 9). The most important and well-known virulence factors are the Apx toxins (I to III), which belong to the family of Repeats in ToXin (RTX) toxins (9, 10). They cause the lysis of different cell types, including red blood cells, alveolar epithelial cells, neutrophils, and macrophages (9, 10).

A wide variety of bacterial species are present in the upper respiratory tract of pigs (11), and are likely to have positive or negative interactions with *A. pleuropneumoniae*. To the best of our knowledge, the negative interactions, such as competition and antagonism, that occur in the porcine respiratory tract and that involve *A. pleuropneumoniae* have not been thoroughly investigated to date. Antagonism is related to the ability of microorganisms to produce antimicrobial substances, including bacteriocins, organic acids, and hydrogen peroxide ( $H_2O_2$ ) (12, 13). Preliminary analyses in our laboratory showed that *Streptococcus pluranimalium* 2N12, which was isolated from a pig nasal sample, is able to antagonize the growth of *A. pleuropneumoniae* in a deferred growth inhibition assay. In the present study, we investigated the  $H_2O_2$ -mediated antagonistic activity of *S. pluranimalium* 2N12 against *A. pleuropneumoniae*.

## MATERIALS AND METHODS

### Bacteria and Growth Conditions

The *A. pleuropneumoniae* strains used in this study (Table 1) were grown in Todd Hewitt Broth (THB; BD-Canada, Mississauga, ON, Canada) supplemented with NAD (20  $\mu$ g/mL; THB-NAD) and incubated in an anaerobic chamber (80%  $N_2$ , 10%  $CO_2$ , 10%  $H_2$ ) at 37°C. *S. pluranimalium* 2N12, which was isolated by our laboratory from the nasal cavity of a healthy pig, was identified by 16S rRNA gene sequencing. It was cultivated in THB and was incubated at 37°C in aerobic conditions.

**TABLE 1 |** Minimum inhibitory concentration (MIC) and minimum bactericidal concentration (MBC) values of  $H_2O_2$  against *A. pleuropneumoniae*.


<i>A. pleuropneumoniae</i> strain	$H_2O_2$ (mM)	
	MIC	MBC
4074 (serovar 1)	1.15–2.3	1.15–2.3
4226 (serovar 2)	1.15–2.3	1.15–2.3
S1421 (serovar 3)	0.57–1.15	0.57–1.15
M62 (serovar 4)	1.15	1.15
K17 (serovar 5a)	1.15	1.15–2.3
81750 (serovar 5b)	2.3	2.3
L20 (serovar 5b)	1.15	1.15
FEM $\phi$ (serovar 6)	0.57	0.57
WF83 (serovar 7)	0.57	0.57
405 (serovar 8)	1.15	1.15
CVJ13261 (serovar 9)	1.15	1.15
D13039 (serovar 10)	1.15–2.3	1.15–2.3
56153 (serovar 11)	1.15	2.3
8328 (serovar 12)	2.3–4.6	2.3–4.6
N-273 (serovar 13)	1.15	1.15
3906 (serovar 14)	0.57–1.15	0.57–1.15
HS143 (serovar 15)	1.15–2.3	1.15–2.3
A85/14 (serovar 16)	0.57–1.15	0.57–1.15
162871 (serovar 17)	0.57–1.15	0.57–1.15
7311555 (serovar 18)	1.15	1.15

### Deferred Growth Inhibition Assay for Detecting the Antagonistic Activity of *S. pluranimalium* Against *A. pleuropneumoniae*

Two- $\mu$ L aliquots of an overnight broth culture of *S. pluranimalium* 2N12 were applied on the surface of THB agar plates. After a 24-h incubation at 37°C to allow bacterial growth, the plates were overlaid with soft THB-NAD agar (0.75%, w/v) that had been inoculated with an overnight culture of either *A. pleuropneumoniae* K17 (biotype 1, serovar 5a), 81750 (biotype 1, serovar 5b), or L20 (biotype 1, serovar 5b) (700  $\mu$ L of bacterial culture in 7 mL of soft THB-NAD agar), and were incubated for a further 24 h at 37°C. The inhibitory zones (in mm) were measured from the edge of the *S. pluranimalium* growth to the margin of the inhibition area. The effect of adding catalase (100 units/mL) to the THB agar plates when growing *S. pluranimalium* was evaluated. Assays were performed in triplicate, and the means  $\pm$  standard deviations (SD) were calculated.

### Determination of $H_2O_2$ Production

The quantification of  $H_2O_2$  production by *S. pluranimalium* 2N12 was assessed using the LAPTg medium described by Alvarez et al. (14). LAPTg medium contains 1.5% (w/v) peptone, 1% (w/v) tryptone, 1% (w/v) yeast extract, 1% (w/v) glucose, and 0.1% (v/v) Tween 80. The pH was adjusted to 6.5. Briefly, *S. pluranimalium* was cultivated overnight in LAPTg, harvested by



**FIGURE 1** | Production of H<sub>2</sub>O<sub>2</sub> by *S. pluranimalium* 2N12. **(A)**: Dose- and time-dependent effect. **(B)**: Time-dependent effect. H<sub>2</sub>O<sub>2</sub> was quantified using a fluorimetric assay. Assays were performed in triplicate in two independent experiments, and the means ± SD were calculated.

**TABLE 2** | Inhibitory zones produced by *S. pluranimalium* 2N12 against *A. pleuropneumoniae* in a deferred growth inhibition assay.

<i>A. pleuropneumoniae</i> strain	Inhibitory zones in mm (mean ± SD)	
	No catalase	With catalase
K17 (serovar 5a)	1.3 ± 0.6	0
81750 (serovar 5b)	4.0 ± 0	0.5 ± 0
L20 (serovar 5b)	6.3 ± 0.6	0.5 ± 0

centrifugation, and suspended in the same medium at an optical density at 660 nm (OD<sub>660</sub>) of 0.6 (~3 × 10<sup>9</sup> colony-forming units [CFU]/mL), 0.4, 0.2, and 0.1. The bacteria were incubated at 37°C with shaking (120 RPM), and samples were taken after 0, 1, and 2 h. In one experiment using an inoculum with an OD<sub>660</sub> of 0.1, the incubation was extended to 24 h. H<sub>2</sub>O<sub>2</sub> in the cell-free supernatants was determined using a fluorimetric H<sub>2</sub>O<sub>2</sub> assay kit (Sigma-Aldrich Canada Co., Oakville, ON, Canada) according to the manufacturer's instructions. Assays were performed in triplicate in three independent experiments, and the means ± SD were calculated.

### Effect of Lactate on H<sub>2</sub>O<sub>2</sub> Production

The effect of exogenous lactate on H<sub>2</sub>O<sub>2</sub> production by *S. pluranimalium* 2N12 was assessed. Lactate was added at concentrations ranging from 1 to 25 mM to the LAPTg medium, and the production of H<sub>2</sub>O<sub>2</sub> was quantified after a 2-h incubation following inoculation (OD<sub>660</sub> = 0.4) as described above. Assays were performed in triplicate in three independent experiments, and the means ± SD were calculated.

### Determination of Minimum Inhibitory Concentrations and Minimum Bactericidal Concentrations of H<sub>2</sub>O<sub>2</sub>

Minimum inhibitory concentrations (MICs) and minimum bactericidal concentrations (MBCs) of H<sub>2</sub>O<sub>2</sub> (Sigma-Aldrich Canada Co.) against twenty strains of *A. pleuropneumoniae* (Table 1) belonging to eighteen different serovars were determined as follows. Briefly, 24-h bacterial cultures (*A. pleuropneumoniae*) in THB-NAD were diluted in fresh broth medium to obtain an OD<sub>660</sub> of 0.2. Equal volumes (100 μL) of bacteria and two-fold serial dilutions of 0.1% H<sub>2</sub>O<sub>2</sub> (corresponding to 29.5 mM) in THB-NAD were mixed in the wells of a 96-well microplate. Control wells with no bacteria or no H<sub>2</sub>O<sub>2</sub> were also prepared. The microplates were incubated (without agitation) at 37°C for 24 h in an anaerobic chamber prior to determining bacterial growth by recording the OD<sub>660</sub> using an xMark Microplate spectrophotometer (Bio-Rad Laboratories Inc., Mississauga, ON, Canada). The MIC value was defined as the lowest concentration of H<sub>2</sub>O<sub>2</sub> that completely prevented bacterial growth. The MBC values were determined by subculturing 5-μL aliquots from each well that exhibited no visible growth on THB-NAD agar plates, which were incubated for 48 h at 37°C in an anaerobic chamber. The MBC value was defined as the lowest concentration of H<sub>2</sub>O<sub>2</sub> at which no colonies formed. Assays were performed in triplicate in three independent experiments.

### Killing Assay of Planktonic *A. pleuropneumoniae* by H<sub>2</sub>O<sub>2</sub> and a Culture Supernatant of *S. pluranimalium*

In a first assay, cells from overnight cultures of *A. pleuropneumoniae* 81750 and K17 were harvested by


centrifugation and were suspended in LAPTg medium to obtain an OD<sub>660</sub> of 0.4. The bacterial suspensions (2 mL) were mixed with 6 mL of H<sub>2</sub>O<sub>2</sub> (in LAPTg medium) to obtain a final concentration of 2.3 mM. The mixtures were incubated anaerobically for 4 h at 37°C prior to assessing bacterial viability by determining the number of CFUs. In a second assay, *S. pluranimalium* 2N12 was cultivated overnight in THB, harvested by centrifugation, and suspended in LAPTg medium to an OD<sub>660</sub> of 0.4. The bacterial suspension was incubated for 2 h with shaking at 37°C. The cell-free culture supernatant was then harvested, adjusted to pH 7.0, and filter-sterilized. The amount of H<sub>2</sub>O<sub>2</sub> in the supernatant was quantified using the fluorimetric assay described above. The *A. pleuropneumoniae* suspensions (2 mL, OD<sub>660</sub> of 0.4) were mixed with 6 mL of the *S. pluranimalium* culture supernatant. The mixture was anaerobically incubated at 37°C for 4 h, and bacterial viability was assessed by determining the CFUs. The effect of pre-treating the culture supernatant of *S. pluranimalium* with catalase (100 units/mL) for 1 h at room temperature prior to performing the assay was assessed. All the assays were performed in triplicate, and the means ± SD were calculated. Given the above viable count methodology, the minimum detection limit is 10<sup>1</sup> CFU/mL.

### Killing Assay of a Biofilm-Like Structure of *A. pleuropneumoniae* by H<sub>2</sub>O<sub>2</sub> and a Culture Supernatant of *S. pluranimalium*

*A. pleuropneumoniae* 81750 and K17 biofilm-like structures were pre-formed overnight (THB-NAD, 37°C, anaerobic chamber) in the wells of a 96-well clear bottom black wall microplate (Greiner Bio-One North America, Monroe, NC, USA). After removing planktonic and loosely-attached bacteria by aspiration, the biofilm-like structures were exposed (4 h, 37°C, anaerobic chamber) to either H<sub>2</sub>O<sub>2</sub> (0.57, 1.15, 2.3, and 4.6 mM) or a culture supernatant of *S. pluranimalium* 2N12 prepared as described above. Biofilm-like structure viability was assessed using the FilmTracer LIVE/DEAD Biofilm Viability kit (Life Technologies Corporation, Eugene, OR, USA) according to the manufacturer's protocol. Assays were performed in triplicate, and the means ± SD were calculated.

### Effect of H<sub>2</sub>O<sub>2</sub> on the Activity of Conventional Antibiotics Against *A. pleuropneumoniae*

Interactions between H<sub>2</sub>O<sub>2</sub> and conventional antibiotics (ceftiofur, penicillin G, tetracycline) used to treat *A. pleuropneumoniae* infections were evaluated using the checkerboard technique (15). H<sub>2</sub>O<sub>2</sub> (from 4.6 mM) was serially diluted two-fold in THB-NAD (100 μL) along the ordinate of a 96-well microplate, while antibiotics (from 2 μg/mL) were serially diluted two-fold in THB-NAD (100 μL) along the abscissa. A cell suspension of *A. pleuropneumoniae* 81750 prepared in THB-NAD and adjusted to an OD<sub>660</sub> of 0.2 was used as the inoculum. The microplate wells were inoculated with 100 μL of bacterial suspension, and the microplates were





**FIGURE 2 |** Dose-dependent effect of exogenous lactate on the production of H<sub>2</sub>O<sub>2</sub> by *S. pluranimalium* 2N12. H<sub>2</sub>O<sub>2</sub> was quantified using a fluorimetric assay. Assays were performed in triplicate in two independent experiments, and the means ± SD were calculated. \*Significantly different at  $p < 0.01$  compared to the control (no lactate).

incubated at 37°C for 24 h. Wells with no bacteria or compounds were used as controls. After the incubation period, bacterial growth was assessed visually. The lowest concentration at which no growth occurred was considered the MIC. The fractional inhibitory concentration index (FICI) was calculated as follows:  $FICI = FIC_A + FIC_B = (MIC_{H_2O_2} \text{ in combination} / MIC_{H_2O_2} \text{ alone}) + (MIC_{\text{Antibiotic in combination}} / MIC_{\text{Antibiotic alone}})$ . An FICI ≤ 0.5 was considered as having a synergistic effect, an FICI > 0.5 and ≤ 1.0 as having an additive effect, an FICI > 1.0 and ≤ 4.0 as having no effect, and an FICI > 4.0 as having an antagonistic effect (15). Two independent assays were performed.

### Effect of Catalase on the Growth of and Biofilm Formation by *S. pluranimalium*

The effect of catalase (6.25, 12.5, 25, 50, 100, and 200 units/mL) on the growth of and biofilm formation by *S. pluranimalium* 2N12 was assessed in a 96-well microplate. Bacteria were cultivated for 20 h, and growth was monitored by recording the OD<sub>660</sub> using a Synergy 2 microplate reader (BioTek Instruments, Winooski, VT, USA). Planktonic and poorly-attached bacterial cells were then removed by aspiration with a 26G needle. Biofilms were stained with 100 μL of 0.01% crystal violet for 15 min, washed with distilled water, and dried at 37°C for 2 h. To release biofilm-embedded crystal violet, 100 μL of 75% ethanol was added, and the plate was shaken for 15 min. The biofilm biomass was estimated by recording the absorbance at 550 nm (A<sub>550</sub>) using an xMark Microplate spectrophotometer. Assays were performed in



triplicate in three independent experiments, and the means ± SD were calculated.


## Statistical Analysis

Statistical analyses were performed using a one-way ANOVA analysis of variance with a *post-hoc* Bonferroni multiple comparison test (GraphPad Software Inc., San Diego, CA,

USA). All results were considered statistically significant at *p* < 0.01.

## RESULTS

The ability of *S. pluranimalium* 2N12 to exert an antagonistic effect on *A. pleuropneumoniae* was first examined using a



deferred growth inhibition assay. As reported in **Table 2**, *A. pleuropneumoniae* 81750 and L20 strains, which belong to serovar 5b, displayed inhibitory zones of 4.0 mm and 6.3 mm, respectively. *A. pleuropneumoniae* K17 (serovar 5a) appeared less sensitive, showing an inhibitory zone of 1.3 mm. The deferred growth inhibition assay was then performed in the presence of catalase to determine whether the inhibition of *A. pleuropneumoniae* may have resulted from the production of  $H_2O_2$  by *S. pluranimalium*. Adding catalase (100 units/mL) resulted in a significant reduction or complete abolition of the inhibitory zones (**Table 2**).

As  $H_2O_2$  is a potential inhibitory compound that is active against *A. pleuropneumoniae*, its production by *S. pluranimalium* 2N12 was confirmed by quantifying  $H_2O_2$  levels in a culture supernatant (LAPTg medium) using a fluorimetric assay. As shown in **Figure 1A**, *S. pluranimalium* dose- and time-dependently produced  $H_2O_2$ . A low bacterial inoculum ( $OD_{660}$  of 0.1) resulted in the production of  $56.3 \mu M$  of  $H_2O_2$  after a 2-h incubation, while the use of a higher bacterial inoculum ( $OD_{660}$  of 0.6) was associated with the production of  $845.5 \mu M$  of  $H_2O_2$ , a 15-fold increase compared to that of the low bacterial inoculum. It was then determined whether a longer incubation time for the low bacterial inoculum ( $OD_{660}$  of 0.1) resulted in the production of higher amounts of  $H_2O_2$ . The results reported in **Figure 1B** show that extending the incubation to 24 h was associated with lower amounts of  $H_2O_2$  compared to the 6-h incubation time.

Lactate oxidase is a bacterial enzyme that converts lactate into pyruvate and  $H_2O_2$ . **Figure 2** indicates that exogenous lactate added to the LAPTg culture medium dose-dependently increased the amount of  $H_2O_2$  produced by *S. pluranimalium*. More specifically, the presence of 25 mM lactate increased the production of  $H_2O_2$  1.57-fold compared to the control (no lactate), suggesting that the production of  $H_2O_2$  by

**TABLE 3 |** FICI values for  $H_2O_2$  in combination with conventional antibiotics on *A. pleuropneumoniae*.


<i>A. pleuropneumoniae</i> strain	Antibiotic	FICI value <sup>a</sup>	Effect
K17	Ceftiofur	Assay 1: 0.266	Synergy
		Assay 2: 0.133	Synergy
	Penicillin G	Assay 1: 0.5	Synergy
		Assay 2: 0.066	Synergy
	Tetracycline	Assay 1: 0.375	Synergy
		Assay 2: 0.25	Synergy
81750	Ceftiofur	Assay 1: 0.313	Synergy
		Assay 2: 0.188	Synergy
	Penicillin G	Assay 1: 1.0	No effect
		Assay 2: 0.75	No effect
	Tetracycline	Assay 1: 2.0	No effect
		Assay 2: 0.625	No effect

<sup>a</sup>FICI  $\leq 0.5$  = synergistic effect, FICI  $> 0.5$  and  $\leq 1.0$  = additive effect, FICI  $> 1.0$  and  $\leq 4.0$  = no effect, FICI  $> 4.0$  = antagonistic effect.

*S. pluranimalium* relies, at least in part, on the activity of lactate oxidase.

The antibacterial activity of  $H_2O_2$  against *A. pleuropneumoniae* strains belonging to eighteen different serovars was evaluated by determining the MIC and MBC values. As reported in **Table 1**, all the strains tested had MICs and MBCs ranging from 0.57 mM (corresponding to 0.002% [v/v]) to 2.3 mM (corresponding to 0.008% [v/v]) for  $H_2O_2$ .

The killing of planktonic *A. pleuropneumoniae* (strains 81750 and K17) caused by either  $H_2O_2$  or a culture supernatant of *S. pluranimalium* (treated or not with catalase) after a 4-h incubation was monitored. As reported in **Figure 3A**,  $H_2O_2$



used at a concentration of 2.3 mM, which corresponded to the MBC, reduced the viability of *A. pleuropneumoniae* 81750 (initial concentration:  $5 \times 10^6$  CFU/mL) and K17 (initial concentration:  $4.45 \times 10^6$  CFU/mL) below the minimum detection limit ( $10^1$  CFU/mL). On the other hand, in the control assay (no H<sub>2</sub>O<sub>2</sub>), the bacterial concentrations increased slightly. Similarly, a culture supernatant of *S. pluranimalium* (containing 0.5 mM H<sub>2</sub>O<sub>2</sub>) significantly reduced the number of planktonic *A. pleuropneumoniae* cells. **Figure 3B** shows that the CFUs for *A. pleuropneumoniae* 81750 dropped from  $4.45 \times 10^6$  CFU/mL to  $2 \pm 0.6 \times 10^3$  CFU/mL, and from  $3.4 \pm 0.4 \times 10^7$  CFU/mL to below the minimum detection limit ( $10^1$  CFU/mL) for *A. pleuropneumoniae* K17. Treating the culture supernatant of *S. pluranimalium* with catalase, which led to a residual concentration of 0.04 mM H<sub>2</sub>O<sub>2</sub>, completely abolished its bactericidal activity.

The ability of H<sub>2</sub>O<sub>2</sub> and the culture supernatant of *S. pluranimalium* to cause the killing and desorption of biofilm-like structures of *A. pleuropneumoniae* 81750 and K17 following a 4-h treatment was then assessed. When used at a high concentration (MBC or two-fold MBC), H<sub>2</sub>O<sub>2</sub> slightly but significantly decreased the viability of both *A. pleuropneumoniae* biofilm-like structures (**Figure 4A**). More specifically, at two-fold MBC (4.6 mM), viability was reduced by  $11.5 \pm 1.4\%$  and  $8.3 \pm 2.7\%$  for strains 81750 and K17, respectively. While H<sub>2</sub>O<sub>2</sub> did not induce biofilm-like structure desorption for *A. pleuropneumoniae* 81750, it caused a dose-dependently desorption of the *A. pleuropneumoniae* K17 biofilm-like structure (**Figure 4B**). At two-fold MBC (4.6 mM), the biofilm-like biomass was reduced by  $64.4 \pm 1.3\%$ . The same effects on *A. pleuropneumoniae* biofilm-like structure killing and desorption were investigated using the culture supernatant of *S. pluranimalium* containing 0.5 mM H<sub>2</sub>O<sub>2</sub>. As reported in **Figure 5**, no significant effects were observed.

The effect of H<sub>2</sub>O<sub>2</sub> on the activity of conventional antibiotics, including ceftiofur, penicillin G, and tetracycline, against *A. pleuropneumoniae* 81750 and K17 was then evaluated. As reported in **Table 3**, synergistic effects were observed for both strains when H<sub>2</sub>O<sub>2</sub> was used in combination with ceftiofur. Synergistic interactions were only observed for strain K17 with the H<sub>2</sub>O<sub>2</sub>/penicillin G and H<sub>2</sub>O<sub>2</sub>/tetracycline combinations.

Preliminary assays showed that *S. pluranimalium* has the ability to form a biofilm. We thus investigated whether H<sub>2</sub>O<sub>2</sub> contributes to biofilm formation by growing *S. pluranimalium* in the presence of various amounts of catalase. On the one hand, the presence of catalase increased the bacterial growth rate, and the highest concentration tested (200 units/mL) also appeared to increase the final biomass as shown by the higher final OD<sub>660</sub> (**Figure 6A**). On the other hand, the presence of catalase dose-dependently reduced biofilm formation (**Figure 6B**). More specifically, when added at a concentration of 200 units/mL, catalase decreased the formation of a biofilm by  $76.3 \pm 1.3\%$ .

## DISCUSSION

A large number of different microorganisms reside in the upper respiratory tract of pigs (11). In the healthy state, these microbial communities live in homeostasis and it can be hypothesized that they protect the animals against external pathogens that may reach this site. This protective effect may rely on the ability of certain commensal bacteria to produce antimicrobial compounds such as bacteriocins, organic acids, and hydrogen peroxide that are active against pathogenic microorganisms (12, 13). In the present study, we investigated the antagonistic activity of *S. pluranimalium* 2N12 against *A. pleuropneumoniae*.

We first confirmed an antimicrobial activity of *S. pluranimalium* 2N12 against *A. pleuropneumoniae*, which

was related to H<sub>2</sub>O<sub>2</sub> production. This is supported by the fact that the ability of a culture supernatant of *S. pluranimalium* 2N12 to induce the killing of planktonic cells of *A. pleuropneumoniae* was totally eliminated following a treatment with catalase. Moreover, commercial H<sub>2</sub>O<sub>2</sub> was highly bactericidal for all serovars of *A. pleuropneumoniae* tested, with MBC values ranging from 0.57 to 2.3 mM. The deleterious effects of H<sub>2</sub>O<sub>2</sub> on *A. pleuropneumoniae* may be linked to the generation of hydroxyl radicals in the presence of Fe(II) once it enters the cells (16), which results in the oxidation of macromolecules such as DNA and proteins.

Lactate oxidase (LctO) is a common H<sub>2</sub>O<sub>2</sub>-producing enzyme in bacteria that catalyzes the formation of pyruvate and H<sub>2</sub>O<sub>2</sub> from lactate and oxygen (17). In the present study, the addition of exogenous lactate increased the production of H<sub>2</sub>O<sub>2</sub> by *S. pluranimalium*, providing support for the key role of LctO. However, other pathways such as those involving pyruvate oxidase and amino acid oxidase (17), which may also contribute to generating H<sub>2</sub>O<sub>2</sub>, should not be excluded. Studies are currently in progress in our laboratory to investigate how environmental parameters modulate H<sub>2</sub>O<sub>2</sub> production by *S. pluranimalium*.

As H<sub>2</sub>O<sub>2</sub> is a harmful byproduct of aerobic metabolism and as *S. pluranimalium* does not produce catalase, it must possess a molecular mechanism to neutralize H<sub>2</sub>O<sub>2</sub>. Similarly to *S. pluranimalium*, *Streptococcus pneumoniae* produces large amounts of H<sub>2</sub>O<sub>2</sub> as a byproduct of its metabolism (18). Several mechanisms have been suggested to explain how *S. pneumoniae* defends against the H<sub>2</sub>O<sub>2</sub>-mediated oxidative stress, including (i) scarcity of proteins with iron-sulfur clusters which can be damaged by reactive oxygen species (ROS) in an iron-dependent manner, (ii) expression of ferritin-like proteins known as Dps (DNA-binding protein from starved cells) or Dpr (Dps-like peroxide resistance), and (iii) production of thiol peroxidase (TpxD) activity (18). The exact mechanism that allows protection of *S. pluranimalium* from H<sub>2</sub>O<sub>2</sub> needs to be characterized.

Evidence was brought that H<sub>2</sub>O<sub>2</sub> production by *S. pluranimalium* is involved in its ability to form a biofilm given that the presence of catalase dose-dependently prevented biofilm formation. H<sub>2</sub>O<sub>2</sub>-mediated biofilm formation has been previously reported for *Streptococcus sanguinis* and *Streptococcus gordonii*, which are primary colonizers of human dental biofilms (19, 20). It has been proposed that H<sub>2</sub>O<sub>2</sub> induces the release of extracellular bacterial DNA, without autolysis, that promotes cell-to-cell adhesion and biofilm formation (20).

*A. pleuropneumoniae* has the ability to form a biofilm (21, 22) that enhances its resistance to antibiotics compared to planktonic cells (23). We showed that treating a pre-formed biofilm-like structure of *A. pleuropneumoniae* with H<sub>2</sub>O<sub>2</sub> at a concentration corresponding to the MBC (2.3 mM) reduces its viability. No killing of the biofilm-like structure was obtained with a culture supernatant of *S. pluranimalium*, which is likely related to the fact that the supernatant contained a low amount of H<sub>2</sub>O<sub>2</sub> (0.5 mM). Additional studies are required to demonstrate the killing effect of H<sub>2</sub>O<sub>2</sub> using more relevant biofilm models of *A. pleuropneumoniae*.

The effect of H<sub>2</sub>O<sub>2</sub> on the activity of conventional antibiotics used to treat *A. pleuropneumoniae* infections was assessed using

the checkerboard technique. Synergistic interactions between H<sub>2</sub>O<sub>2</sub> and some antibiotics, including ceftiofur, penicillin G, and tetracycline, were demonstrated, particularly against *A. pleuropneumoniae* K17. This observation was in agreement with the study of Sgibnev and Kremleva (24) who investigated the influence of various microbial metabolites on the antibiotic sensitivity of bacteria. The authors reported that H<sub>2</sub>O<sub>2</sub> was the most effective bacterial metabolite for increasing the sensitivity of both Gram-positive and Gram-negative bacteria to several antibiotics. They proposed that H<sub>2</sub>O<sub>2</sub> may cause a shift in the balance of pro-oxidants and antioxidants in bacteria and that the resulting oxidative stress enhances the effects of antibiotics on the target bacteria.

Based on our results, the production of H<sub>2</sub>O<sub>2</sub> by *S. pluranimalium* could be regarded as a potential protection mechanism of the upper respiratory tract against H<sub>2</sub>O<sub>2</sub>-sensitive pathogens such as *A. pleuropneumoniae*. Interestingly, previous studies have documented the role of H<sub>2</sub>O<sub>2</sub> produced by commensal streptococci colonizing the oral cavity in controlling cariogenic bacteria (mainly *Streptococcus mutans*) (25–27). It is worth mentioning that the presence of catalase positive staphylococci in the upper respiratory tract of pigs (11) may attenuate the beneficial impact of H<sub>2</sub>O<sub>2</sub>.

The resistance of *A. pleuropneumoniae* to various antibiotics, including tetracycline, ampicillin, and penicillin, is on the increase and is a growing concern (28–30). The identification of alternative strategies for controlling *A. pleuropneumoniae* infections is thus of great interest. In this regard, further studies are required to explore the possibility of using *S. pluranimalium* as a probiotic to antagonize respiratory pathogens such as *A. pleuropneumoniae*.

## CONCLUSIONS

Based on our results, the production of H<sub>2</sub>O<sub>2</sub> by *S. pluranimalium* could be regarded as a potential protective mechanism of the upper respiratory tract against H<sub>2</sub>O<sub>2</sub>-sensitive pathogens such as *A. pleuropneumoniae*.

## DATA AVAILABILITY STATEMENT

The original contributions presented in the study are included in the article/supplementary material, further inquiries can be directed to the corresponding author.

## AUTHOR CONTRIBUTIONS

MF, MG, and DG conceived and designed the experiments. KV performed the experimental assays and the statistical analysis. DG drafted and finalized the manuscript. All authors contributed to the article and approved the submitted version.

## FUNDING

This study was supported by Fonds de recherche du Québec—Nature et technologies (2018-PR-205462).

## REFERENCES

- Gottschalk M. Actinobacillosis. In: Karriker L, Ramirez A, Schwartz K, Stevenson G, Zimmerman J, editors. *Diseases of Swine*. 10th ed. Hoboken, NJ: Wiley (2012). p. 653–69.
- Sassu EL, Bossé JT, Tobias TJ, Gottschalk M, Langford PR, Hennig-Pauka I. Update on *Actinobacillus pleuropneumoniae*—knowledge, gaps and challenges. *Transbound Emerg Dis*. (2017) 65:72–90. doi: 10.1111/tbed.12739
- Stringer OW, Bossé JT, Lacouture S, Gottschalk M, Fodor L, Angen Ø, et al. Proposal of *Actinobacillus pleuropneumoniae* serovar 19, and reformulation of previous multiplex PCRs for capsule-specific typing of all known serovars. *Vet Microbiol*. (2021) 255:109021. doi: 10.1016/j.vetmic.2021.109021
- Lacouture S, Gottschalk M. Distribution of *Actinobacillus pleuropneumoniae* (from 2015 to June 2020) and *Glaesserella parasuis* (from 2017 to June 2020) serotypes isolated from diseased pigs in Quebec. *Can Vet J*. (2020) 61:1261–3.
- Dubreuil JD, Jacques M, Mittal KR, Gottschalk M. *Actinobacillus pleuropneumoniae* surface polysaccharides: their role in diagnosis and immunogenicity. *Anim Health Res Vet*. (2000) 1:73–93. doi: 10.1017/S1466252300000074
- Schumerk L, Hoeltig D, Waldmann KH, Valentin-Weigand P, Rohde J. Sero- and apx-typing of German *Actinobacillus pleuropneumoniae* field isolates from 2010 to 2019 reveals a predominance of serovar 2 with regular apx-profile. *Vet Res*. (2021) 52:10. doi: 10.1186/s13567-020-00890-x
- Sarkozi R, Makrai L, Fodor L. *Actinobacillus pleuropneumoniae* serotypes in Hungary. *Acta Vet Hung*. (2018) 66:343–9. doi: 10.1556/004.2018.031
- Bossé JT, Janson H, Sheehan BJ, Beddek AJ, Rycroft AN, Kroll JS, et al. *Actinobacillus pleuropneumoniae*: pathobiology and pathogenesis of infection. *Microbes Infect*. (2002) 4:225–35. doi: 10.1016/S1286-4579(01)01534-9
- Chiers K, De Waele T, Pasmans F, Ducatelle R, Haesebrouck F. Virulence factors of *Actinobacillus pleuropneumoniae* involved in colonization, persistence and induction of lesions in its porcine host. *Vet Res*. (2010) 41:65. doi: 10.1051/vetres/20100037
- Schaller A, Kuhnert P, de la Puente-Redondo VA, Nicolet J, Frey J. Apx toxins in Pasteurellaceae species from animals. *Vet Microbiol*. (2000) 74:365–76. doi: 10.1016/S0378-1135(00)00204-2
- Pirolo M, Espinosa-Gongora C, Bogaert D, Guardabassi L. The porcine respiratory microbiome: recent insights and future challenges. *Anim Microbiome*. (2021) 3:9. doi: 10.1186/s42523-020-00070-4
- Kanmani P, Satish Kumar R, Yuvaraj N, Paari KA, Pattukumar V, Arul V. Probiotics and its functionally valuable products—a review. *Crit Rev Food Sci Nut*. (2013) 53:641–58. doi: 10.1080/10408398.2011.553752
- Khaneghah AM, Abhari K, Es I, Soares MB, Oliveira RBA, Hosseini H, et al. Sant'Ana AS. Interactions between probiotics and pathogenic microorganisms in hosts and food: A review. *Trends Food Sci Technol*. (2020) 95:205–18. doi: 10.1016/j.tifs.2019.11.022
- Alvarez MF, Medina R, Pasteris SE, Strasser de Saad AM, Sesma F. Glycerol metabolism of *Lactobacillus rhamnosus* ATCC 7469: cloning and expression of two glycerol kinase genes. *J Mol Microbiol Biotechnol*. (2004) 7:170–81. doi: 10.1159/000079826
- Eliopoulos GM, Moellering RC. Antimicrobial combinations. In: Lorian V, editor. *Antibiotics in Laboratory Medicine*. Baltimore, MD: The Williams and Wilkins Co. (1996), p. 330–96.
- Imlay JA. Pathways of oxidative damage. *Annu Rev Microbiol*. (2003) 57:395–418. doi: 10.1146/annurev.micro.57.030502.090938
- Redanz S, Cheng X, Giacaman RA, Pfeifer CS, Merritt J, Kreth J. Live and let die: hydrogen peroxide production by the commensal flora and its role in maintaining a symbiotic microbiome. *Mol Oral Microbiol*. (2018) 33:337–52. doi: 10.1111/omi.12231
- Yesilkaya H, Farshchi Andisi V, Andrew PW, Bijlsma JJE. *Streptococcus pneumoniae* and reactive oxygen species: an unusual approach to living with radicals. *Trends Microbiol*. (2013) 21:187–95. doi: 10.1016/j.tim.2013.01.004
- Duan D, Scofield JA, Zhou X, Wu H. Fine-tuned production of hydrogen peroxide promotes biofilm formation of *Streptococcus parasanguinis* by a pathogenic cohabitant *Aggregatibacter actinomycetemcomitans*. *Environ Microbiol*. (2016) 18:4023–36. doi: 10.1111/1462-2920.13425
- Kreth J, Vu H, Zhang Y, Herzberg MC. Characterization of hydrogen peroxide-induced DNA release by *Streptococcus sanguinis* and *Streptococcus gordonii*. *J Bacteriol*. (2009) 191:6281–91. doi: 10.1128/JB.00906-09
- Hathroubi S, Loera-Muro A, Guerrero-Barrera AL, Tremblay YND, Jacques M. *Actinobacillus pleuropneumoniae* biofilms: role in pathogenicity and potential impact for vaccination development. *Anim Health Res Rev*. (2017) 19:17–30. doi: 10.1017/S146625231700010X
- Labrie J, Pelletier-Jacques G, Deslandes V, Ramjeet M, Auger E, Nash JHE, et al. Effects of growth conditions on biofilm formation by *Actinobacillus pleuropneumoniae*. *Vet Res*. (2010) 41:03. doi: 10.1051/vetres/2009051
- Izano EA, Sadovskaya I, Vinogradov E, Mulks MH, Vellyagounder K, Ragnath C, et al. Poly-N-acetylglucosamine mediates biofilm formation and antibiotic resistance in *Actinobacillus pleuropneumoniae*. *Microb Pathog*. (2007) 43:1–9. doi: 10.1016/j.micpath.2007.02.004
- Sgibnev A, Kremleva E. Influence of hydrogen peroxide, lactic acid, and surfactants from vaginal lactobacilli on the antibiotic sensitivity of opportunistic bacteria. *Probiotics Antimicrob Proteins*. (2017) 9:131–41. doi: 10.1007/s12602-016-9238-6
- Giacaman RA, Torres S, Gomez Y, Munoz-Sandoval C, Kreth J. Correlation of *Streptococcus mutans* and *Streptococcus sanguinis* colonization and *ex vivo* hydrogen peroxide production in carious lesion-free and high caries adults. *Arch Oral Biol*. (2015) 60:154–9. doi: 10.1016/j.archoralbio.2014.09.007
- Herrero ER, Slomka V, Bernaerts K, Boon N, Hernandez-Sanabria E, Passoni BB, et al. Teughels. Anti-microbial effects of commensal oral species are regulated by environmental factors. *J Dent*. (2016) 47:23–33. doi: 10.1016/j.jdent.2016.02.007
- Kreth J, Zhang Y, Herzberg MC. Streptococcal antagonism in oral biofilms: *Streptococcus sanguinis* and *Streptococcus gordonii* interference with *Streptococcus mutans*. *J Bacteriol*. (2008) 190:4632–40. doi: 10.1128/JB.00276-08
- Archambault M, Harel J, Goure J, Tremblay YD, Jacques M. 2012. Antimicrobial susceptibilities and resistance genes of Canadian isolates of *Actinobacillus pleuropneumoniae*. *Microb Drug Resist*. (2012) 18:198–206. doi: 10.1089/mdr.2011.0150
- Michael GB, Bossé JT, Schwarz S. 2017. Antimicrobial resistance in Pasteurellaceae of veterinary origin. *Microbiol Spectr*. (2012) 6:3. doi: 10.1128/microbiolspec.ARBA-0022-2017
- Vanni MM, Merenda G, Barigazzi C, Garbarino A, Luppi R, Tognetti L, et al. Antimicrobial resistance of *Actinobacillus pleuropneumoniae* isolated from swine. *Vet Microbiol*. (2012) 23:172–7. doi: 10.1016/j.vetmic.2011.10.022

**Conflict of Interest:** The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

**Publisher's Note:** All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Copyright © 2021 Vaillancourt, Frenette, Gottschalk and Grenier. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.